JP2013541010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541010A5 JP2013541010A5 JP2013533913A JP2013533913A JP2013541010A5 JP 2013541010 A5 JP2013541010 A5 JP 2013541010A5 JP 2013533913 A JP2013533913 A JP 2013533913A JP 2013533913 A JP2013533913 A JP 2013533913A JP 2013541010 A5 JP2013541010 A5 JP 2013541010A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- pbmcs
- pharmaceutical composition
- glatiramer acetate
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 23
- 102000013691 Interleukin-17 Human genes 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 14
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 14
- 229960003776 glatiramer acetate Drugs 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 8
- 102100037850 Interferon gamma Human genes 0.000 claims 8
- 108010074328 Interferon-gamma Proteins 0.000 claims 8
- 108010002350 Interleukin-2 Proteins 0.000 claims 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 8
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 239000000090 biomarker Substances 0.000 claims 4
- 238000010254 subcutaneous injection Methods 0.000 claims 4
- 239000007929 subcutaneous injection Substances 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 238000010257 thawing Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39196810P | 2010-10-11 | 2010-10-11 | |
| US61/391,968 | 2010-10-11 | ||
| PCT/US2011/055588 WO2012051106A1 (en) | 2010-10-11 | 2011-10-10 | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093309A Division JP2016188214A (ja) | 2010-10-11 | 2016-05-06 | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013541010A JP2013541010A (ja) | 2013-11-07 |
| JP2013541010A5 true JP2013541010A5 (https=) | 2016-07-28 |
Family
ID=45938670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013533913A Withdrawn JP2013541010A (ja) | 2010-10-11 | 2011-10-10 | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
| JP2016093309A Withdrawn JP2016188214A (ja) | 2010-10-11 | 2016-05-06 | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093309A Withdrawn JP2016188214A (ja) | 2010-10-11 | 2016-05-06 | グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8709433B2 (https=) |
| EP (1) | EP2627669B1 (https=) |
| JP (2) | JP2013541010A (https=) |
| KR (1) | KR20140019296A (https=) |
| AU (1) | AU2011313842B2 (https=) |
| BR (1) | BR112013008573A2 (https=) |
| CA (1) | CA2814500A1 (https=) |
| EA (1) | EA025780B1 (https=) |
| ES (1) | ES2602977T3 (https=) |
| IL (1) | IL225118A (https=) |
| MX (1) | MX347871B (https=) |
| NZ (2) | NZ703122A (https=) |
| PL (1) | PL2627669T3 (https=) |
| PT (1) | PT2627669T (https=) |
| WO (1) | WO2012051106A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2612001T4 (es) | 2009-08-20 | 2018-02-07 | Yeda Research & Development Company, Ltd. | Terapia de baja frecuencia con acetato de glatirámero |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
| MX2015004563A (es) * | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| WO2014159685A2 (en) | 2013-03-14 | 2014-10-02 | Mylan Inc. | Glatiramer acetate response biomarker mrna potency assay |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9995734B2 (en) | 2013-10-24 | 2018-06-12 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US20160213633A1 (en) * | 2015-01-28 | 2016-07-28 | Teva Pharmaceutical Industries, Ltd. | Method of inducing anti-glatiramer acetate antibody response |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HUE071047T2 (hu) | 2016-08-31 | 2025-07-28 | Mapi Pharma Ltd | Glatiramer-acetátot tartalmazó depórendszerek |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| EP3844501A1 (en) * | 2018-08-30 | 2021-07-07 | Essen Instruments, Inc. d/b/a Essen BioScience, Inc. | Methods for determining concentration of low and high concentration proteins in a single sample |
| WO2025181335A1 (en) * | 2024-02-29 | 2025-09-04 | Grifols Worldwide Operations Limited | Methods of treating a cognitive impairment |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| SI1115743T1 (sl) | 1998-09-25 | 2010-01-29 | Yeda Res And Dev Co Ltd The We | Polipeptidi, sorodni kopolimeru 1, za uporabo kot markerji molekulske mase in za terapevtsko uporabo |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| CA2355400A1 (en) | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co., Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| PT1248643E (pt) | 2000-01-20 | 2005-10-31 | Yeda Res & Dev | Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| WO2001060392A1 (en) | 2000-02-18 | 2001-08-23 | Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| CA2411536A1 (en) | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| DK1294390T3 (da) | 2000-06-07 | 2006-04-03 | Yeda Res & Dev | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| SI1459065T1 (sl) | 2001-12-04 | 2010-11-30 | Teva Pharma | Postopki za merjenje potentnosti glatiramer acetata |
| IL160105A0 (en) | 2001-12-06 | 2004-06-20 | Yeda Res & Dev | Vaccine for treatment of motor neurone diseases |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| CN102580069B (zh) | 2003-01-07 | 2015-09-30 | 耶达研究及发展有限公司 | 用于治疗性免疫接种的含共聚物1的滴眼用疫苗 |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| PT1638589E (pt) | 2003-05-14 | 2014-06-12 | Teva Pharma | Terapia combinada com acetato de glatirâmero e mitoxantrona para o tratamento da esclerose múltipla |
| WO2005007673A2 (en) * | 2003-07-03 | 2005-01-27 | Rush University Medical Center | Immunogenic peptides |
| CA2540701A1 (en) | 2003-09-29 | 2005-04-07 | Chugai Seiyaku Kabushiki Kaisha | Proteins expressed in nk cells |
| US20050170004A1 (en) | 2003-10-31 | 2005-08-04 | Vered Rosenberger | Nanoparticles for drug delivery |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| AU2005218625A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US20090048181A1 (en) * | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| US7495072B2 (en) | 2004-09-09 | 2009-02-24 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| AU2005302500B2 (en) | 2004-10-29 | 2008-11-27 | Sandoz Ag | Processes for preparing glatiramer |
| KR20070108388A (ko) | 2005-02-02 | 2007-11-09 | 테바 파마슈티컬 인더스트리즈 리미티드 | 가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법 |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| PL1848415T3 (pl) | 2005-02-17 | 2013-10-31 | Teva Pharma | Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego |
| WO2006116602A2 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| US20100062471A1 (en) * | 2005-09-29 | 2010-03-11 | Ppd Biomarker Discovery Sciences Llc | Biomarkers for Multiple Sclerosis and Methods of Use Thereof |
| WO2007081975A2 (en) * | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| WO2008006026A1 (en) | 2006-07-05 | 2008-01-10 | Momenta Pharmaceuticals, Inc. | Improved process for the preparation of copolymer-1 |
| WO2009002515A1 (en) * | 2007-06-25 | 2008-12-31 | Vertex Pharmaceuticals Incorporated | Th-17 cells |
| US20090149541A1 (en) | 2007-11-28 | 2009-06-11 | Yafit Stark | Method of delaying the onset of clinically definite multiple sclerosis |
| EP2113560A1 (en) * | 2008-04-28 | 2009-11-04 | TXCell | Compositions for treating an arthritic condition |
| EP2335066B1 (en) * | 2008-09-19 | 2016-12-28 | University of Utah Research Foundation | Methods for prediction of multiple sclerosis disease and therapy response |
| RS52367B (sr) | 2009-07-15 | 2012-12-31 | Teva Pharmaceutical Industries Ltd. | Formulacije glatiramer acetata smanjene zapremine i postupci primene |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| ES2612001T4 (es) | 2009-08-20 | 2018-02-07 | Yeda Research & Development Company, Ltd. | Terapia de baja frecuencia con acetato de glatirámero |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| NZ703122A (en) | 2010-10-11 | 2016-06-24 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| KR20140101730A (ko) | 2011-10-10 | 2014-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| CA2895457A1 (en) | 2012-12-21 | 2014-06-26 | Teva Pharmaceutical Industries Ltd. | Oral transmucosal delivery of glatiramer acetate |
| JP2016503803A (ja) | 2012-12-21 | 2016-02-08 | テバ ファーマシューティカル インダストリーズ リミティド | 酢酸グラチラマーの経粘膜送達 |
| JP2016504039A (ja) | 2013-01-04 | 2016-02-12 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテート関連医薬品の特性決定 |
| MX2015012156A (es) | 2013-03-12 | 2015-11-30 | Teva Pharma | Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer. |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2011
- 2011-10-10 NZ NZ703122A patent/NZ703122A/en not_active IP Right Cessation
- 2011-10-10 AU AU2011313842A patent/AU2011313842B2/en not_active Ceased
- 2011-10-10 WO PCT/US2011/055588 patent/WO2012051106A1/en not_active Ceased
- 2011-10-10 KR KR1020137012245A patent/KR20140019296A/ko not_active Ceased
- 2011-10-10 EA EA201390543A patent/EA025780B1/ru not_active IP Right Cessation
- 2011-10-10 US US13/269,913 patent/US8709433B2/en not_active Expired - Fee Related
- 2011-10-10 ES ES11833199.0T patent/ES2602977T3/es active Active
- 2011-10-10 MX MX2013003929A patent/MX347871B/es active IP Right Grant
- 2011-10-10 CA CA2814500A patent/CA2814500A1/en not_active Abandoned
- 2011-10-10 JP JP2013533913A patent/JP2013541010A/ja not_active Withdrawn
- 2011-10-10 PL PL11833199T patent/PL2627669T3/pl unknown
- 2011-10-10 BR BR112013008573A patent/BR112013008573A2/pt not_active IP Right Cessation
- 2011-10-10 PT PT118331990T patent/PT2627669T/pt unknown
- 2011-10-10 EP EP11833199.0A patent/EP2627669B1/en active Active
- 2011-10-10 NZ NZ609938A patent/NZ609938A/en not_active IP Right Cessation
-
2013
- 2013-03-07 IL IL225118A patent/IL225118A/en not_active IP Right Cessation
-
2014
- 2014-04-11 US US14/250,955 patent/US9063153B2/en not_active Expired - Fee Related
-
2015
- 2015-05-07 US US14/706,843 patent/US9625473B2/en not_active Expired - Fee Related
-
2016
- 2016-05-06 JP JP2016093309A patent/JP2016188214A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541010A5 (https=) | ||
| Sahr et al. | Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone | |
| Wu et al. | Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory | |
| Morandi et al. | NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN‐γ secretion | |
| Mondal et al. | Protection of Tregs, suppression of Th1 and Th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline | |
| Zhu et al. | Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives | |
| CN101385742A (zh) | 来自人类血液的cd4+cd25+调节性t细胞 | |
| US20230084300A1 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| Al‐Attiyah et al. | Comparative analysis of spontaneous and mycobacterial antigen‐induced secretion of Th1, Th2 and pro‐inflammatory cytokines by peripheral blood mononuclear cells of tuberculosis patients | |
| US12403105B2 (en) | Diagnosis and treatment of vitiligo | |
| Sheng et al. | Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination | |
| CN104395461B (zh) | 得到单核细胞或nk细胞的方法 | |
| Ramos et al. | The autoimmune nature of post-infarct myocardial healing: oral tolerance to cardiac antigens as a novel strategy to improve cardiac healing | |
| Hu et al. | Berberine protects against hepatocellular carcinoma progression by regulating intrahepatic T cell heterogeneity | |
| Lipscomb et al. | Ectopic T-bet expression licenses dendritic cells for interleukin (IL)-12-independent priming of Type-1 T cells in vitro | |
| US20160067272A1 (en) | Methods for treating immune diseases | |
| US20230183370A1 (en) | Stem cell immunomodulatory therapy for covid-19 infection | |
| Rezaei et al. | In vitro effects of sodium benzoate on Th1/Th2 deviation in patients with multiple sclerosis | |
| JP2023504734A (ja) | 制御性Ｔ細胞（Ｔｒｅｇ）組成物及び神経変性疾患を治療するための方法 | |
| Rossi et al. | Tumor-intrinsic or drug-induced immunogenicity dictates the therapeutic success of the PD1/PDL axis blockade | |
| Wu et al. | α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis | |
| CN105925526A (zh) | 一种增强cik细胞活性的方法与cik细胞及其制备方法和应用 | |
| Cao et al. | Characteristics and potential roles of natural killer cells during SARS-CoV-2 infection | |
| Huth et al. | 429 Prohapten-activation by human cutaneous cytochrome P450 isoenzymes–identified with a modified KeratinoSens assay | |
| US11191782B2 (en) | Anti-tumor T cells and their preparation using IL-6 |